Ra Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary peptide chemistry platform to develop therapeutics for the treatment of diseases that are caused by excessive or uncontrolled activation of the complement system, a primary component of the immune system. Co. is developing its primary product candidate, zilucoplan, a synthetic, macrocyclic peptide C5 inhibitor, formulated for self-administered, subcutaneous injection, which is an injection into the tissue under the skin, for the treatment of various complement-mediated diseases, including generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and other complement-mediated disorders. We show 15 historical shares outstanding datapoints in our RARX shares outstanding history coverage, used to compute RARX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RARX market cap history over the course of time is important for investors
interested in comparing RARX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RARX versus a peer is one thing; comparing
RARX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RARX can fluctuate over the course of history.
With this page we aim to empower investors researching RARX by allowing them to research the RARX market cap history. |
Free RARX Email Alerts:
Video: The Importance of Market Cap
